June 28, 2022
The Committee for Medicinal Products for Human Use (CHMP) recommends approving upadacitinib 15 mg, once daily, for the treatment of active non-radiographic axial spondyloarthritis in adults patients with inflammation and inadequate response to NSAIDs.
June 14, 2022
Désirée van der Heijde, MD, PhD, explains the results of a recent trial evaluating the safety and efficacy of bimekizumab in patients with active ankylosing spondylitis.
June 03, 2022
Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."
June 03, 2022
Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.
May 11, 2022
Of 185 outpatients that completed the questionnaire, 146 patients (78.9%) were considered to have poor adherence to exercise therapy.
May 04, 2022
The European Alliance of Associations for Rheumatology (EULAR) recommends screening and early management of cardiovascular disease in patients with radiographic axial spondyloarthritis.
April 25, 2022
A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.
March 22, 2022
“Understanding the impact of axSpA on pregnancy outcomes is a vital component of improving management of women with axSpA at every stage of their lives,” investigators stated.
January 18, 2022
Bimekizumab, an interleukin 17A (IL-17A) and IL-17F inhibitor, met both primary and secondary endpoints for treating adult patients with non-radiographic axial spondyloarthritis.
December 09, 2021
Jessica Walsh, MD, explains the importance of understanding treatment satisfaction and decision-making in patients with axial spondyloarthritis based on patient-reported outcomes.